Monday, January 9, 2012

Recent Research Papers of Sujit Bhattacharya & Jayanthi A.P. of CSSP

Investigating the role of policies, strategies, and governance in China's emergence as a global nanotech player
by Sujit Bhattacharya; M. Bhati; A. P. Kshitij
2011 Atlanta Conference on Science and Innovation Policy (September 2011), pg. 1-14

China has challenged the dominance of advanced OECD countries in high technologies by emerging as a leading country in nanotechnology; projected as a key technology of the 21st century. Stakes are high as estimated market value and economic and social benefits are immense for countries that can attain competency in this technology. The study makes a broad assessment of nanotechnology performance of China; to reveal to what extent it is making an assertion in this technology. We then investigate macro and micro level policies and strategies in China's emergence as a key player in nanotechnology. China's emergence in nanotechnology is discussed in a broader context to distill how a country that is still at a low end of technology value chain with limited innovative ability has been able to create capacity and capability in a high technology area. This can be learning for countries in transition that face similar constraints in trying to become an `innovation oriented' society.
Full-text Link

Research and Innovation for Drug Development in Neglected Diseases: A Case Study of India
by Sujit Bhattacharya; Jayanthi A. Pushkaran
African Journal of Science Technology and Development, 2011, 3(3), p. 236-258.

This study investigated the research and innovation in 'neglected diseases' in India and the various modalities being undertaken to develop 'novel' drugs for these diseases. In spite of increase in scientific research and patent filing, examination of Indian pharmaceutical firm's activities shows that only a few firms are involved in the domain of neglected disease. Government is trying to bridge the 'translational gap' by stimulating public-private research partnership; however, private firms primarily exhibit profit motive for coming into public partnership. This model, as the evidences show, is not suitable for drug development in neglected diseases. The study explores other models that can broadly be placed under open innovation and argues that they are more promising for drug development in neglected diseases. It calls for more attention to these approaches as they provide incentives for actors to participate and moves away from the 'market centric' focus on drug development by firms leading to research only for lifestyle diseases effecting the north.

For full-text papers please contact the authors.

No comments: